Oral Presentation No. 090 Pleiotropic effect of antiplatelet ticagrelor: expression of CYP4F2 in HUVEC and HepG2. (21st October 2022)

• Record Type: Journal Article
• Authors: Ciapiene, Ieva; Meskauskaite, Ugne; Andruskeviciute, Silvija; Lesauskaite, Vaiva; Tatarunas, Vacis
• Is Part Of: Cardiovascular research. Volume 118(2022)Supplement 2
• Publication Date: 2022-10-21
• Subjects: ticagrelor -- CYP4F2 -- HUVEC -- HepG2 -- ischemic heart disease; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Periodicals; 616.1
• DOI: 10.1093/cvr/cvac157.076
• Languages: English
• ISSNs: 0008-6363

Abstract

Abstract: Background: Ticagrelor is a first drug of a new chemical class cyclopentyltriazolopyrimidines and a third-generation P2Y12 inhibitor that targets and directly binds platelet P2Y12 receptors. It is recommended to be given as a dual antiplatelet therapy (DAPT) with aspirin for the prevention of thrombotic events and the following ischemic heart disease. Ticagrelor is also known to have pleiotropic effects of unknown mechanisms. It is questioned whether ticagrelor could influence the expression of cytochrome P450 4F2 (CYP4F2) enzyme involved in the resolution of inflammation and biosynthesis of pro-inflammatory eicosanoids. This study aimed to investigate if ticagrelor could alter the expression of CYP4F2 and its encoded protein concentration in both endothelial cells (human umbilical vein endothelial cells, HUVEC) and the metabolism of various xenobiotics performing, CYPs-rich liver cells (HepG2). Material and methods: The expression of CYP4F2 was determined in HUVEC and HepG2 cell lines by qPCR on real time thermal cycler ABI 7900HT (Applied Biosystems, USA). CYP4F2 protein concentration was determined with sandwich enzyme immunoassay kit for CYP4F2 (Cloud-Clone Corp., USA). Results and conclusions: Ticagrelor was observed to reduce the expression of CYP4F2 in HUVEC and HepG2 cell lines. It also reduced CYP4F2 protein levels in HUVEC cells. Thus, ticagrelor may have a protective role in endothelial cells and reduce vascular inflammation. Funding sources: This work was supported by the Research Council of Lithuania under Grant 09.3.3.-LMT-K-712-16-0187.